Bibliographic Details
| Title: |
A Preclinical Immunogenicity Study of the Recombinant Human Papillomavirus Nine-Valent Virus-like Particle Vaccine |
| Authors: |
Dan Xu, Jia-Dai Li, Jiao An, Xin-Xing Ma, Xiao-Liang Wang, Zheng Zhou, Hai-Ping Liu, Mei-Jun Diao, Yuan-Xiang Jiang, Ling-Yun Zhou, Xin Tong, Chen-Liang Zhou |
| Source: |
Vaccines, Vol 12, Iss 12, p 1356 (2024) |
| Publisher Information: |
MDPI AG, 2024. |
| Publication Year: |
2024 |
| Collection: |
LCC:Medicine |
| Subject Terms: |
human papillomavirus (HPV), virus-like particles (VLPs), vaccines, immunogenicity, protective efficacy, Medicine |
| More Details: |
Background: Cervical cancer is associated with persistent infection of high-risk human papillomaviruses (HPVs). Prophylactic HPV vaccines have been recommended and have significant efficacy in preventing cervical cancer. Multivalent HPV vaccines have a better preventative effect on HPV-related diseases. However, there is currently only one nine-valent HPV vaccine on the market: Gardasil® 9. The development of new HPV vaccines is still urgent in order to achieve the goal of eliminating cervical cancer as proposed by the WHO. Methods: In this study, we developed a nine-valent recombinant HPV virus-like particle (VLP) vaccine (HPV-9 vaccine) containing HPV type 6, 11, 16, 18, 31, 33, 45, 52, and 58 antigens, with an adjuvant of aluminum phosphate (AlPO4). The type-specific L1 proteins were recombinantly expressed using Pichia pastoris, followed by self-assembly into VLPs. Immunogenicity studies of the HPV-9 vaccine were performed using rodents (mice and rats) and non-human primates (macaques) as animal models. Results: Immunogenicity studies showed that the HPV-9 vaccine is able to elicit a robust and long-lasting neutralizing antibody response in rodents (mice and rats) and non-human primates (cynomolgus macaque) models. The HPV-9 vaccine shows immunogenicity comparable to that of Walrinvax® and Gardasil® 9. Conclusions: In summary, this study provides a comprehensive investigation of the immunogenicity of the HPV-9 vaccine, including its immune persistence. These findings, derived from using models of diverse animal species, contribute valuable insights into the potential efficacy of the vaccine candidate in clinical settings. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2076-393X |
| Relation: |
https://www.mdpi.com/2076-393X/12/12/1356; https://doaj.org/toc/2076-393X |
| DOI: |
10.3390/vaccines12121356 |
| Access URL: |
https://doaj.org/article/ae7419693a7c4afab93167371bf1a15c |
| Accession Number: |
edsdoj.7419693a7c4afab93167371bf1a15c |
| Database: |
Directory of Open Access Journals |
